April 2025 – Page 4

As J&J aims to ‘fundamentally change’ how bladder cancer type is treated, ImmunityBio plays defense

3 months ago talkbio0Tagged Anktiva, BCG-Unresponsive, bladder-sparing treatment, Carcinoma in Situ, gemcitabine releasing system, ImmunityBio, in situ, Malignant neoplasm of urinary bladder, Non-Muscle Invasive Bladder Neoplasms, TAR 200

TAR-200, bladder cancer, gemcitabine releasing system, non-muscle invasive bladder cancer (NMIBC), Johnson & Johnson, ImmunityBio, Anktiva, BCG-unresponsive, carcinoma in situ (CIS), bladder-sparing treatment

J&J reports durability data for bladder cancer ‘pretzel’ drug after FDA filing

3 months ago talkbio0Tagged Malignant neoplasm of urinary bladder, TAR 200, United States Food and Drug Administration, Urinary Bladder

Urinary Bladder, TAR 200, United States Food and Drug Administration, Malignant neoplasm of urinary bladder

Roche’s WRN Inhibitor Shows Promising Early Results in MSI-H Tumors at AACR25

3 months ago talkbio0Tagged AACR25, Cancer Research, High-Frequency Microsatellite Instability, Inhibitor, Neoplasms, Roche (company), Werner Syndrome

Roche, WRN inhibitor, MSI-H tumors, AACR25, cancer research, oncology

Akeso’s PD-1 inhibitor notches inaugural FDA nod for nasopharyngeal cancer

3 months ago talkbio0Tagged Akeso, Akeso 's, Anniko, Approved, Inhibitor, Nasopharyngeal carcinoma, PDCD1 gene, United States Food and Drug Administration

United States Food and Drug Administration, Approved, Akeso, Nasopharyngeal carcinoma, PDCD1 gene, Inhibitor, Akeso ‘s, Anniko

Gilead, ‘closely attuned to’ potential US policy shifts, stands by long-acting PrEP launch

3 months ago talkbio0Tagged Gilead, HIV Prevention, launch, Lenacapavir, long-acting, Pre-Exposure Prophylaxis, U.S., United States Food and Drug Administration

Lenacapavir, Pre-Exposure Prophylaxis, United States Food and Drug Administration, launch, HIV prevention, long-acting, U.S., Gilead

Caribou cuts 32% of staff, further purges pipeline to focus on 2 oncology CAR-T prospects

3 months ago talkbio0Tagged 32%, Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010, CAR-T, Cell Therapy, Clustered Regularly Interspaced Short Palindromic Repeats, Leukemia, Myelocytic, Acute, Neoplasms, Reindeer, Staff, United States Food and Drug Administration

Reindeer, CAR-T, Staff, Neoplasms, Cell Therapy, Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010, Clustered Regularly Interspaced Short Palindromic Repeats, Leukemia, Myelocytic, Acute, United States Food and Drug Administration, 32%